Analytical Data
-
基因名
SLC35A2
-
简介
SLC35A2 is a key transmembrane protein that acts as an antiporter to transport uridine diphosphate galactose (UDP-galactose) into the Golgi apparatus. The process involves the exchange of UDP-galactose with UMP and exhibits versatility through exchange with AMP and CMP. SLC35A2 Protein, Human (sf9, His, MBP, FLAG) is the recombinant human-derived SLC35A2 protein, expressed by sf9 insect cells , with N-MBP, C-Flag, N-8*His labeled tag.
- Application
-
别名
SLC35A2; UDP-galactose translocator; Solute carrier family 35 member A2; UDP-galactose transporter; UDP-Gal-Tr; UGT
-
种属
Human
-
表达系统
Baculovirus
-
标签
N-MBP;C-Flag;N-8*His
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
P78381
-
表达区间
A2-S396
-
蛋白长度
Partial
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
SLC35A2 is a member of the solute carrier family that plays a crucial role in nucleotide sugar transport, particularly in the transport of UDP-galactose and other activated sugar nucleotides into the Golgi apparatus. This process is essential for glycosylation, a post-translational modification that affects protein folding, stability, and cell signaling. Mutations in the SLC35A2 gene have been linked to congenital disorders of glycosylation, notably a rare genetic disease characterized by developmental delays, neurological issues, and other systemic complications, underscoring the protein's significance in human health. Investigating the recombinant SLC35A2 protein facilitates a deeper understanding of its function and the molecular mechanisms underlying its role in glycosylation. It also provides a platform for exploring potential therapeutic strategies for associated disorders. By producing and characterizing this recombinant protein, researchers aim to elucidate its transport mechanism, substrate specificity, and interactions with other glycosylation-related enzymes, thereby paving the way for advancements in treating glycosylation defects and enhancing our overall understanding of cellular glycosylation processes.
